Company intelligence / Profile preview

SensoDetect

Ownership: Private
Employees: ~2
Development stage: Other

Overview

The company’s BERA technology has been clinically validated over decades of research at Lund University. It provides objective, non-invasive measurement of brainstem responses to sound stimuli to aid in the diagnosis of ADHD and autism. Recent AI initiatives aim to further improve accuracy and expand diagnostic capabilities. The product has been launched globally with ongoing refinement.

Therapeutic areas: PsychiatryNeurology
Modalities: DeviceNon-pharmacological therapy (diagnostic technology)Artificial intelligence platform (for diagnostics)
Industry: Physiological Monitoring

Partnerships

Collaborations with neuroscience/data science partners on AI initiative; specific names not disclosed as of June 2025

Beyond the preview

Go deeper on SensoDetect.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SensoDetect.

Explore the full profile